GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Clarity Pharmaceuticals CU6.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

1.57

+4.67%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in AUD, from our data supplier.

FY2026

Revenue

—

FY2018FY2026

Net income

−A$107.1m

FY2018FY2026

Free cash flow

−A$92.9m

FY2018FY2026

Shareholders' equity

A$186.1m

FY2018FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue—A$9.5mA$11.5mA$9.8mA$6.5mA$3.2mA$2.8mA$2.6mA$2.5m
Gross profit−A$283,530A$9.5mA$11.5mA$9.7mA$6.4mA$3.2mA$2.8mA$2.6mA$2.4m
Research and developmentA$91.1mA$66.9mA$45.8mA$31.5mA$18.9mA$9.7mA$4.0mA$2.1mA$1.5m
Operating income−A$118.9m−A$69.1m−A$44.8m−A$36.2m−A$17.0m−A$13.5m−A$9.8m−A$6.4m−A$4.2m
Net income−A$107.1m−A$64.3m−A$42.3m−A$24.6m−A$23.8m−A$10.2m−A$7.0m−A$3.7m−A$1.7m
Diluted earnings per share-0.29-0.18-0.13-0.09-0.09-0.04-0.03-0.01-0.01

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assetsA$199.1mA$101.2mA$154.6mA$76.9mA$99.8mA$22.6mA$9.1mA$10.4mA$2.8m
Cash and short-term investmentsA$178.3mA$84.1mA$136.5mA$65.0mA$92.3mA$18.9mA$6.3mA$8.4mA$1.7m
Total liabilitiesA$13.0mA$10.9mA$8.3mA$7.7mA$7.6mA$2.3mA$956,094A$1.1mA$857,043
Debt———————−A$146,489—
Shareholders' equityA$186.1mA$90.2mA$146.3mA$69.2mA$92.2mA$20.3mA$8.2mA$9.2mA$1.9m
Shares outstanding373m364m317m263m260m257m257m256m257m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−A$92.5m−A$54.8m−A$43.2m−A$27.5m−A$13.3m−A$7.7m−A$6.8m−A$3.7m−A$1.5m
Capital spending−A$306,922−A$182,743−A$504,005−A$46,562−A$213,148−A$60,311−A$14,496−A$15,670−A$5,377
Free cash flow−A$92.9m−A$55.0m−A$43.7m−A$27.5m−A$13.5m−A$7.7m−A$6.8m−A$3.7m−A$1.5m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Mar 2024Dec 2023Sept 2023
Revenue——A$4.8mA$4.7mA$6.1mA$3.0mA$5.4mA$2.7m
Gross profit−A$132,910−A$150,620A$4.8mA$4.7mA$6.1mA$3.0mA$2.7mA$2.7m
Operating income−A$56.4m−A$62.5m−A$39.3m−A$29.8m−A$26.6m−A$13.3m−A$23.6m−A$9.1m
Net income−A$51.6m−A$55.5m−A$40.7m−A$23.6m−A$25.1m−A$12.6m−A$17.2m−A$8.6m
Diluted earnings per share-0.14-0.15-0.11-0.07-0.08-0.04-0.07-0.03
Cash from operations−A$44.0m−A$47.0m−A$24.0m−A$30.0m−A$16.0m−A$8.0m−A$26.0m−A$13.0m
Total assetsA$199.1mA$255.7mA$101.2mA$137.1mA$154.6mA$154.6mA$58.2mA$58.2m
Cash and short-term investmentsA$178.3mA$226.2mA$84.1mA$111.2mA$136.5mA$136.5mA$38.0mA$38.0m
Shareholders' equityA$186.1mA$232.8mA$90.2mA$127.4mA$146.3mA$146.3mA$53.1mA$53.1m

Financial ratios

Data as of 4 Nov 2026

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin—100.0%100.0%99.0%99.3%99.5%99.4%
Operating margin—-730.2%-389.3%-350.0%-467.5%-419.0%-338.5%
Net margin—-679.5%-367.8%-251.0%-367.8%-319.8%-249.3%
Return on equity-57.6%-71.3%-28.9%-35.6%-25.8%-50.4%—
Return on assets-53.8%-63.6%-27.4%-32.0%-23.8%-45.2%—
Free cash flow yield-17.9%-10.9%-9.8%-7.6%-3.7%-2.1%—
Revenue growth—-17.8%17.4%51.7%102.1%14.6%5.5%
Earnings growth66.6%51.9%72.0%3.6%132.4%47.0%—
Current ratio16.09x9.69x19.05x10.17x13.26x10.00x—
Debt to equity—0.00x0.00x0.00x0.00x0.00x0.00x
Equity ratio93.5%89.2%94.6%90.0%92.4%89.7%—
R&D as a share of sales—706.8%397.9%321.0%292.6%302.7%144.4%
Buybacks as a share of market value-2.5%-14.7%-20.7%-1.1%-1.0%-0.1%—

Growth per year

Compound annual rate

3 years5 years10 years
Operating income48.7%54.5%—
Net income63.3%60.0%—

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021
Price to earnings-5.6-19.1-31.3-20.3-10.8-18.6
Price to sales—129.9114.950.939.859.5

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.